Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs)

Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs)

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Cell Types</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Basal Ganglia, Striatum</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>GABA (inhibitory)</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Medium Spiny Neuron (MSN)</td>
</tr>
<tr>
<td class="label">Dopamine Receptor</td>
<td>D2R (Drd2)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Huntington's Disease, Schizophrenia</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:4023029](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4023029](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">D2 agonists</td>
<td>Indirect pathway inhibition</td>
</tr>
<tr>
<td class="label">A2A antagonists</td>
<td>D2-MSN disinhibition</td>

Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs)

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Cell Types</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Basal Ganglia, Striatum</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>GABA (inhibitory)</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Medium Spiny Neuron (MSN)</td>
</tr>
<tr>
<td class="label">Dopamine Receptor</td>
<td>D2R (Drd2)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Huntington's Disease, Schizophrenia</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:4023029](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:4023029](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">D2 agonists</td>
<td>Indirect pathway inhibition</td>
</tr>
<tr>
<td class="label">A2A antagonists</td>
<td>D2-MSN disinhibition</td>
</tr>
<tr>
<td class="label">PDE10A inhibitors</td>
<td>cAMP modulation</td>
</tr>
<tr>
<td class="label">Deep brain stimulation</td>
<td>GPi/SNr output modulation</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>mHTT silencing</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Direct (D1-MSNs)</td>
</tr>
<tr>
<td class="label">Effect on movement</td>
<td>Facilitate ("Go")</td>
</tr>
<tr>
<td class="label">Dopamine effect</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Output target</td>
<td>GPi/SNr</td>
</tr>
<tr>
<td class="label">Neuropeptides</td>
<td>Substance P, Dynorphin</td>
</tr>
<tr>
<td class="label">Clinical correlation</td>
<td>HD early loss</td>
</tr>
</table>

Striatal Indirect Pathway Medium Spiny Neurons (D2 Msns) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Striatal Indirect Pathway Medium Spiny [Neurons](/entities/neurons) (D2-MSNs), also known as "No-Go" neurons, are essential for movement suppression and action inhibition. These neurons express dopamine D2 receptors and form the indirect pathway that prevents unwanted movements.

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: indirect pathway medium spiny neuron (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

External Database Links

• [Cell Ontology (CL:4023029)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)
• [OBO Foundry (CL:4023029)](http://purl.obolibrary.org/obo/CL_4023029)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Taxonomy & Classification

External Database Links

• [Cell Ontology (CL:4023029)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4023029)
• [OBO Foundry (CL:4023029)](http://purl.obolibrary.org/obo/CL_4023029)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)

Morphology and Markers

• Soma: Medium-sized (10-15 μm diameter) GABAergic neurons
• Dendrites: Highly spiny, receiving cortical glutamatergic input
• Axon: Projects to external globus pallidus (GPe), not directly to GPi/SNr
• Key Markers:
• D2 dopamine receptor (DRD2)
• Enkephalin (Penk gene)
• Adenosine A2A receptor (ADORA2A)
• DARPP-32 (PPP1R1B)
• RGS9 (Regulator of G protein signaling 9)
• ETBR (Endothelin receptor type B)

Normal Function

The indirect pathway suppresses movement through the following circuit:

Cortex ( glutamatergic) → D2-MSNs → GPe (inhibition) → STN (disinhibition) → GPi/SNr (excitation) → Thalamus (inhibition) → Cortex (suppression)

Key Functions:

Electrophysiology:

• Resting membrane potential: ~-80 mV
• Action potential duration: 1-2 ms
• Input resistance: 50-100 MΩ
• Lower basal activity compared to D1-MSNs due to D2 autoreceptor inhibition

Disease Vulnerability

Parkinson's Disease

• Hyperactivity: D2-MSNs become overactive in PD due to loss of dopaminergic inhibition
• Mechanism: Reduced dopamine → less D2 receptor activation → D2-MSN disinhibition
• Bradykinesia: Overactive indirect pathway excessively suppresses movement
• Therapeutic target: D2 agonists (pramipexole, ropinirole) reduce D2-MSN activity indirectly
• DBS effects: STN DBS reduces indirect pathway output

Huntington's Disease

• Early vulnerability: D2-MSNs are MORE affected than D1-MSNs in early HD
• Mechanism: Differential vulnerability due to distinct transcriptional profiles
• Clinical correlation: D2-MSN loss correlates with psychiatric symptoms and cognitive deficits
• Selective degeneration: Preclinical HD shows D2-MSN dysfunction before D1-MSNs

Schizophrenia

• D2 hyperactivity: Increased D2-MSN activity contributes to positive symptoms
• Treatment: D2 antagonists (antipsychotics) reduce indirect pathway activity
• Cognitive deficits: Indirect pathway dysfunction affects cognitive flexibility

Molecular Pathways

Dopamine Signaling in D2-MSNs:

Gene Expression Profile:

• Upregulated in D2-MSNs: DRD2, ADORA2A, PENK, GPR6, PDE10A, ANK1
• Differential HD vulnerability: Lower BDNF expression, impaired mitochondrial function

Therapeutic Implications

Comparison: Direct vs Indirect Pathway

See Also

• [Striatal Direct Pathway Medium Spiny Neurons (D1-MSNs)striatal-direct-pathway-medium-spiny-neurons)
• [Striatal Cholinergic Interneurons](/cell-types/striatal-cholinergic-interneurons)
• [Striatal Fast-Spiking Interneurons](/cell-types/striatal-fast-spiking-interneurons)
• [External Globus Pallidus (GPe) Neurons](/external-globus-pallidus-(gpe)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)
• [Subthalamic Nucleus (STN) Neurons](/subthalamic-nucleus-(stn)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)-neurons)
• [Huntington's Disease](/diseases/huntington-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Basal Ganglia](/brain-regions/basal-ganglia)

Background

The study of Striatal Indirect Pathway Medium Spiny Neurons (D2 Msns) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

^[1] Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990.

^[2] Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron. 2008.

^[3] Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989.

^[4] Raymond LA, André VM, Cepeda C, et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic activity and neuronal excitability. Philos Trans R Soc B. 2011.

^[5] Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci. 2004.

^[6] Surmeier DJ, Plotkin J, Shen W. Dopamine and synaptic plasticity in basal ganglia circuits. Neural Plast. 2009.

^[7] Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014.

^[8] Freeze BS, Kravitz AV, Hammack N, Berke JD. Optogenetic manipulation of neural activity in freely moving rodents. Methods. 2011.

Pathway Diagram

The following diagram shows the key molecular relationships involving Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs) discovered through SciDEX knowledge graph analysis: